Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company IOptima Ltd. yesterday announced that, following a presentation of its OT-135 device at an ophthalmology conference in India, it has received orders for ten of its laser treatment systems for glaucoma. The company added that demand for the system was greater, but that together with its Indian partner, Care Group subsidiary Intraocular Care pvt Ltd., the company decided to initially place it at only leading medical centers in the country.
The medical centers made down payments for the laser-based systems, and undertook to treat a minimum number of patients. IOptima estimates that the ten systems will carry out 3,000 procedures in the first year of operation.
The company did not disclose the price, but it is supposed to be competitive compared with the $200-300 cost of glaucoma medication.
Bio-Light's share rose 2.9% yesterday and rose a further 1.7% at the opening today to NIS 0.82, giving a market cap of NIS 590 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 28, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010